Central nervous system lymphoma

Andres J M Ferreri, Lisa M. DeAngelis

Research output: Chapter in Book/Report/Conference proceedingChapter

3 Citations (Scopus)

Abstract

Introduction A variety of lymphomas can involve the central nervous system (CNS), at different phases of their evolution, in both immunocompetent and immunocompromised individuals. They represent a heterogeneous group of malignancies, with variable clinical and behavioral characteristics, requiring different therapeutic approaches. In this chapter, the therapeutic management of these malignancies will be analyzed separately in three main entities: primary CNS lymphomas (PCNSL), secondary CNS lymphomas (SCNSL) and other, less common, forms of CNS lymphomas. The vast majority of CNS lymphomas are diffuse large B-cell lymphomas (DLBCL) that share the morphological and immunophenotypic characteristics similar to those of DLBCLs encountered elsewhere. They may show a perivascular growth pattern. The perivascular infiltrate is associated with increased reticulin fibres and the periphery of areas of involvement frequently shows astrocyte gliosis. Many immunocompromised patients show features similar to Burkitt's lymphoma, while others show a more immunoblastic morphology. Rare cases of small lymphocytic, lymphoplasmacytic and T-cell lymphoma similar to those seen in tissue outside the CNS have been described. Secondary involvement by lymphoma originating elsewhere is also encountered. Immunophenotypically CNS lymphomas recapitulate the staining pattern of similar lymphomas encountered outside the CNS. The DLBCLs are positive for CD20 and CD79a with expression of bcl-2 protein. A proportion express CD10 and bcl-6, but they are usually negative for CD5 and CD23. Large B-cell lymphomas in immunocompromised patients frequently contain Epstein–Barr virus (EBV).

Original languageEnglish
Title of host publicationLymphoma: Pathology, Diagnosis and Treatment
PublisherCambridge University Press
Pages200-214
Number of pages15
ISBN (Print)9780511663369, 9780521865449
DOIs
Publication statusPublished - Jan 1 2007

Fingerprint

Lymphoma
Central Nervous System
Immunocompromised Host
B-Cell Lymphoma
Reticulin
Gliosis
Burkitt Lymphoma
Lymphoma, Large B-Cell, Diffuse
T-Cell Lymphoma
Astrocytes
Neoplasms
Staining and Labeling
Viruses
Therapeutics
Growth
Proteins

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Ferreri, A. J. M., & DeAngelis, L. M. (2007). Central nervous system lymphoma. In Lymphoma: Pathology, Diagnosis and Treatment (pp. 200-214). Cambridge University Press. https://doi.org/10.1017/CBO9780511663369.015

Central nervous system lymphoma. / Ferreri, Andres J M; DeAngelis, Lisa M.

Lymphoma: Pathology, Diagnosis and Treatment. Cambridge University Press, 2007. p. 200-214.

Research output: Chapter in Book/Report/Conference proceedingChapter

Ferreri, AJM & DeAngelis, LM 2007, Central nervous system lymphoma. in Lymphoma: Pathology, Diagnosis and Treatment. Cambridge University Press, pp. 200-214. https://doi.org/10.1017/CBO9780511663369.015
Ferreri AJM, DeAngelis LM. Central nervous system lymphoma. In Lymphoma: Pathology, Diagnosis and Treatment. Cambridge University Press. 2007. p. 200-214 https://doi.org/10.1017/CBO9780511663369.015
Ferreri, Andres J M ; DeAngelis, Lisa M. / Central nervous system lymphoma. Lymphoma: Pathology, Diagnosis and Treatment. Cambridge University Press, 2007. pp. 200-214
@inbook{cd61a86e7a084312984c45e4da67f045,
title = "Central nervous system lymphoma",
abstract = "Introduction A variety of lymphomas can involve the central nervous system (CNS), at different phases of their evolution, in both immunocompetent and immunocompromised individuals. They represent a heterogeneous group of malignancies, with variable clinical and behavioral characteristics, requiring different therapeutic approaches. In this chapter, the therapeutic management of these malignancies will be analyzed separately in three main entities: primary CNS lymphomas (PCNSL), secondary CNS lymphomas (SCNSL) and other, less common, forms of CNS lymphomas. The vast majority of CNS lymphomas are diffuse large B-cell lymphomas (DLBCL) that share the morphological and immunophenotypic characteristics similar to those of DLBCLs encountered elsewhere. They may show a perivascular growth pattern. The perivascular infiltrate is associated with increased reticulin fibres and the periphery of areas of involvement frequently shows astrocyte gliosis. Many immunocompromised patients show features similar to Burkitt's lymphoma, while others show a more immunoblastic morphology. Rare cases of small lymphocytic, lymphoplasmacytic and T-cell lymphoma similar to those seen in tissue outside the CNS have been described. Secondary involvement by lymphoma originating elsewhere is also encountered. Immunophenotypically CNS lymphomas recapitulate the staining pattern of similar lymphomas encountered outside the CNS. The DLBCLs are positive for CD20 and CD79a with expression of bcl-2 protein. A proportion express CD10 and bcl-6, but they are usually negative for CD5 and CD23. Large B-cell lymphomas in immunocompromised patients frequently contain Epstein–Barr virus (EBV).",
author = "Ferreri, {Andres J M} and DeAngelis, {Lisa M.}",
year = "2007",
month = "1",
day = "1",
doi = "10.1017/CBO9780511663369.015",
language = "English",
isbn = "9780511663369",
pages = "200--214",
booktitle = "Lymphoma: Pathology, Diagnosis and Treatment",
publisher = "Cambridge University Press",

}

TY - CHAP

T1 - Central nervous system lymphoma

AU - Ferreri, Andres J M

AU - DeAngelis, Lisa M.

PY - 2007/1/1

Y1 - 2007/1/1

N2 - Introduction A variety of lymphomas can involve the central nervous system (CNS), at different phases of their evolution, in both immunocompetent and immunocompromised individuals. They represent a heterogeneous group of malignancies, with variable clinical and behavioral characteristics, requiring different therapeutic approaches. In this chapter, the therapeutic management of these malignancies will be analyzed separately in three main entities: primary CNS lymphomas (PCNSL), secondary CNS lymphomas (SCNSL) and other, less common, forms of CNS lymphomas. The vast majority of CNS lymphomas are diffuse large B-cell lymphomas (DLBCL) that share the morphological and immunophenotypic characteristics similar to those of DLBCLs encountered elsewhere. They may show a perivascular growth pattern. The perivascular infiltrate is associated with increased reticulin fibres and the periphery of areas of involvement frequently shows astrocyte gliosis. Many immunocompromised patients show features similar to Burkitt's lymphoma, while others show a more immunoblastic morphology. Rare cases of small lymphocytic, lymphoplasmacytic and T-cell lymphoma similar to those seen in tissue outside the CNS have been described. Secondary involvement by lymphoma originating elsewhere is also encountered. Immunophenotypically CNS lymphomas recapitulate the staining pattern of similar lymphomas encountered outside the CNS. The DLBCLs are positive for CD20 and CD79a with expression of bcl-2 protein. A proportion express CD10 and bcl-6, but they are usually negative for CD5 and CD23. Large B-cell lymphomas in immunocompromised patients frequently contain Epstein–Barr virus (EBV).

AB - Introduction A variety of lymphomas can involve the central nervous system (CNS), at different phases of their evolution, in both immunocompetent and immunocompromised individuals. They represent a heterogeneous group of malignancies, with variable clinical and behavioral characteristics, requiring different therapeutic approaches. In this chapter, the therapeutic management of these malignancies will be analyzed separately in three main entities: primary CNS lymphomas (PCNSL), secondary CNS lymphomas (SCNSL) and other, less common, forms of CNS lymphomas. The vast majority of CNS lymphomas are diffuse large B-cell lymphomas (DLBCL) that share the morphological and immunophenotypic characteristics similar to those of DLBCLs encountered elsewhere. They may show a perivascular growth pattern. The perivascular infiltrate is associated with increased reticulin fibres and the periphery of areas of involvement frequently shows astrocyte gliosis. Many immunocompromised patients show features similar to Burkitt's lymphoma, while others show a more immunoblastic morphology. Rare cases of small lymphocytic, lymphoplasmacytic and T-cell lymphoma similar to those seen in tissue outside the CNS have been described. Secondary involvement by lymphoma originating elsewhere is also encountered. Immunophenotypically CNS lymphomas recapitulate the staining pattern of similar lymphomas encountered outside the CNS. The DLBCLs are positive for CD20 and CD79a with expression of bcl-2 protein. A proportion express CD10 and bcl-6, but they are usually negative for CD5 and CD23. Large B-cell lymphomas in immunocompromised patients frequently contain Epstein–Barr virus (EBV).

UR - http://www.scopus.com/inward/record.url?scp=53249126225&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=53249126225&partnerID=8YFLogxK

U2 - 10.1017/CBO9780511663369.015

DO - 10.1017/CBO9780511663369.015

M3 - Chapter

AN - SCOPUS:53249126225

SN - 9780511663369

SN - 9780521865449

SP - 200

EP - 214

BT - Lymphoma: Pathology, Diagnosis and Treatment

PB - Cambridge University Press

ER -